guest ::
| Home > Publications database > Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay > print |
| Home > Publications database > Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay > print |
| 001 | 823892 | ||
| 005 | 20210129224859.0 | ||
| 024 | 7 | _ | |a 10.1515/hsz-2016-0153 |2 doi |
| 024 | 7 | _ | |a 1431-6730 |2 ISSN |
| 024 | 7 | _ | |a 1437-4315 |2 ISSN |
| 024 | 7 | _ | |a WOS:000397610800005 |2 WOS |
| 024 | 7 | _ | |a 2128/18372 |2 Handle |
| 024 | 7 | _ | |a altmetric:13527416 |2 altmetric |
| 024 | 7 | _ | |a pmid:27811340 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-06524 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Kravchenko, Kateryna |0 P:(DE-Juel1)136806 |b 0 |
| 245 | _ | _ | |a Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay |
| 260 | _ | _ | |a Berlin [u.a.] |c 2017 |b de Gruyter |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1490772506_2451 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Early diagnostics at the preclinical stage of Alzheimer’s disease is of utmost importance for drug development in clinical trials and prognostic guidance. Since soluble Aβ oligomers are considered to play a crucial role in the disease pathogenesis, several methods aim to quantify Aβ oligomers in body fluids such as cerebrospinal fluid (CSF) and blood plasma. The highly specific and sensitive method surface-based fluorescence intensity distribution analysis (sFIDA) has successfully been established for oligomer quantitation in CSF samples. In our study, we explored the sFIDA method for quantitative measurements of synthetic Aβ particles in blood plasma. For this purpose, EDTA, citrate and heparin treated blood plasma samples from five individual donors were spiked with Aβ coated silica nanoparticles (Aβ-SiNaPs) and were applied to the sFIDA assay. Based on the assay parameters linearity, coefficient of variation and limit of detection, we found that EDTA plasma yields the most suitable parameter values for quantitation of Aβ oligomers in sFIDA assay with a limit of detection of 16 fM. |
| 536 | _ | _ | |a 553 - Physical Basis of Diseases (POF3-553) |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Kulawik, Andreas |0 P:(DE-Juel1)162310 |b 1 |u fzj |
| 700 | 1 | _ | |a Hülsemann, Maren |0 P:(DE-Juel1)145968 |b 2 |
| 700 | 1 | _ | |a Kühbach, Katja |0 P:(DE-Juel1)145440 |b 3 |u fzj |
| 700 | 1 | _ | |a Zafiu, Christian |0 P:(DE-Juel1)162137 |b 4 |u fzj |
| 700 | 1 | _ | |a Herrmann, Yvonne |0 P:(DE-Juel1)159122 |b 5 |u fzj |
| 700 | 1 | _ | |a Linnartz, Christina |0 P:(DE-Juel1)145159 |b 6 |u fzj |
| 700 | 1 | _ | |a Peters, Luriano |0 P:(DE-Juel1)145123 |b 7 |u fzj |
| 700 | 1 | _ | |a Bujnicki, Tuyen |0 P:(DE-Juel1)162212 |b 8 |u fzj |
| 700 | 1 | _ | |a Willbold, Johannes |0 P:(DE-Juel1)159192 |b 9 |u fzj |
| 700 | 1 | _ | |a Bannach, Oliver |0 P:(DE-Juel1)157832 |b 10 |u fzj |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 11 |e Corresponding author |u fzj |
| 773 | _ | _ | |a 10.1515/hsz-2016-0153 |g Vol. 0, no. 0 |0 PERI:(DE-600)1466062-3 |n 4 |p 465–475 |t Biological chemistry |v 398 |y 2017 |x 1437-4315 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/823892/files/Analysis%20of%20anticoagulants%20for%20blood-based%20quantitation%20of%20amyloid%20%CE%B2%20oligomers%20in%20the%20sFIDA%20assay_2016.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/823892/files/Analysis%20of%20anticoagulants%20for%20blood-based%20quantitation%20of%20amyloid%20%CE%B2%20oligomers%20in%20the%20sFIDA%20assay_2016.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:823892 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)162310 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)145440 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)162137 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)159122 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)145159 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)145123 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)162212 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)159192 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)157832 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOL CHEM : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
| 980 | 1 | _ | |a FullTexts |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|